Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Bevacizumab + Tivantinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bevacizumab | Avastin | VEGF Antibody 11 VEGFR Inhibitor (Pan) 32 | Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov). | |
Tivantinib | ARQ197|ARQ 197|ARQ-197 | MET Inhibitor 52 | Tivantinib (ARQ197) is a selective MET inhibitor, which may induce cell death in tumor cells overexpressing MET, although the antimitotic effect may be more responsible for the anti-tumor activity (PMID: 28246274, PMID: 32569187, PMID: 32073648). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01749384 | Phase I | Bevacizumab + Tivantinib | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | Completed | USA | 0 |